P4ML Partners with Rady Children’s Institute to Expand Genomic Newborn Screening in EMEAI

IRELAND—P4ML, a technology partner specializing in precision medicine based in Ireland, has announced a significant collaboration with the Rady Children’s Institute for Genomic Medicine (RCIGM) in San Diego, California.

This partnership makes P4ML one of the first biotechnology companies to join the BeginNGS® global newborn screening program.

This announcement follows an earlier collaboration where Qatar’s Sidra Medicine partnered with RCIGM to launch the advanced genome-based newborn screening program, BeginNGS, at Sidra Medicine.

Through this new partnership, BeginNGS® and P4ML seek to expand the scope of newborn screening and promote multi-omics research that combines data from various biological sources.

P4ML will lead the implementation efforts across the Europe, Middle East, Africa, and India (EMEAI) region, leveraging its strong scientific foundation rooted in Ireland.

The company brings extensive expertise in managing health data governance, harmonizing secondary use of health information, deploying trusted research environments (TREs), and integrating multi-omics technology for better healthcare outcomes.

Patrick J. Moloney, Co-Founder of P4ML, emphasized that the company’s mission combines patient empathy with scientific excellence.

 He explained that advancing rare disease research, supporting the United Nations Sustainable Development Goals (SDGs), and delivering on corporate social responsibility (CSR) commitments are central to P4ML’s work.

Moloney stated that P4ML is proud to work alongside leading pharmaceutical institutions, research centers, and health systems to shape the future of newborn screening.

He further highlighted that with BeginNGS already backed by a strong international consortium, P4ML is excited to contribute its expertise.

 The company aims to ensure families across the EMEAI region gain from earlier disease detection, improved treatment outcomes, and faster access to life-changing therapies.

This aligns with BeginNGS’s not-for-profit approach to expanding newborn screening.

The founders of P4ML have deep experience in both small- and large-molecule drug discovery, grounded in Ireland’s vibrant pharmaceutical and biotechnology sectors.

By combining newborn genomic information with advanced molecular platforms, this collaboration is expected to accelerate the development of therapies for rare diseases.

P4ML will oversee practical rollout efforts, which have already begun across the Middle East and North Africa region in 2025.

The program enables newborn screening for more than 1,000 treatable genetic conditions.

Stephen Kingsmore, MD, DSc, President and CEO of RCIGM, noted that expanding international technology partnerships is vital to understanding the incidence of rare diseases worldwide and identifying suitable treatments early in life or even before symptoms appear.

He described this as a shared vision driving BeginNGS’s growth through global collaborations.

Additionally, Tom DeFay, PhD, Vice Chair of BeginNGS and Deputy Head of Diagnostics at Alexion, AstraZeneca Rare Disease, noted that living with a rare disease can create health inequalities.

However, reducing the long and difficult diagnostic process helps promote health equity.

DeFay expressed enthusiasm for continuing support of the BeginNGS Consortium to extend access to crucial diagnostic tools worldwide.

This collaboration marks a significant step in global efforts to enhance newborn screening, accelerate research into rare diseases, and bring life-saving therapies to more families across diverse regions.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.